Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Kite initiates phase I study of KITE-718 in advanced cancers

May 17, 2017

Tella Pharma's TLP0-001 studied in Japanese trial for treatment of pancreatic cancer

May 17, 2017

TPVdelta66R/mIL-2 as a novel immunovirotherapy for melanoma

May 17, 2017

Glenmark Pharmaceuticals cleared to begin phase I study of GBR-1342

May 16, 2017

Advaxis reports data from phase I study of axalimogene filolisbac

May 16, 2017

Immunomic Therapeutics and Annias enter license agreement for cancer immunotherapy technology

May 16, 2017

SB-415286 provides small molecule inhibition of PD-1 transcription

May 15, 2017

rAd.DCN.GM induces antitumor effect in a murine colorectal cancer model

May 12, 2017

NG34scFvPD-1 preclinical data show promise for glioblastoma treatment

May 12, 2017

PACIFIC trial of durvalumab in stage III NSCLC meets PFS primary endpoint

May 12, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...